Early study backs Pharmacyclics' MRI (magnetic resonance imaging) agent:
This article was originally published in Clinica
Executive Summary
Pharmacyclics has presented additional data supporting the use of its texaphyrin MRI-based agent for detecting vulnerable atherosclerotic plaque. Preclinical data, presented at this month's Society for Cardiac Magnetic Resonance in San Francisco, showed the gadolinium-based texaphyrin compound localised in plaque and enhanced MRI signal in atherosclerotic animal models. The Sunnyvale, California firm is currently developing Antrin, a texaphyrin-based, light-activated product for treating peripheral arterial disease and coronary artery disease.
You may also be interested in...
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.